R. Timothy Webb

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Vera Hirsh, Luis Paz‐Ares, Michael Boyer et al. · Journal of Clinical Oncology · 2011 · 137 citations · Full text

Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis

Paul J. Hesketh, Richard J. Gralla, R. Timothy Webb et al. · Journal of Clinical Oncology · 1999 · 114 citations

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia

Michael Auerbach, Peter T. Silberstein, R. Timothy Webb et al. · American Journal of Hematology · 2010 · 88 citations · Full text

Iron Metabolism, Pharmacotherapy, Iron Deficiency +17

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

Chao Li, Lowell L. Hart, Taofeek K. Owonikoko et al. · Cancer Chemotherapy and Pharmacology · 2021 · 16 citations · Full text

A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

J. P. Allerton, Christopher Hagenstad, R. Timothy Webb et al. · Journal of Clinical Oncology · 2006 · 14 citations

Phase Ii Evaluation, Paclitaxel Protein-bound, Metastatic Breast Cancer +15